Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Porphysome mediated delivery of interleukin-2 and in vivo tracking of double negative T-cells for adoptive cell therapy to treat acute myeloid leukemia
FY 2015-16
Summary
Acute myeloid leukemia (AML) is a cancer of early stage immune cells and affects mainly individuals over 60 years of age. Since a variety of genetic defects can result in AML, tumors can be different in different individuals. This heterogeneity makes AML difficult to treat with current options like chemotherapy and bone marrow transplantation. With a five year survival rate of 25%, new therapies are needed to improve patient survival. One promising therapy is adoptive cell therapy, in which the patient's immune cells are removed, cloned and injected back into the body to kill tumor cells. However, not all immune cells reach the tumor site and immune cells have a short lifetime of action. To address these problems, we propose a novel method of adoptive cell therapy, in which immune cells are attached to special nanoparticles. These nanoparticles demonstrate imaging abilities and can be loaded with immune-boosting agents. In this way, we can track the real time movement of immune cells and enhance their ability to kill tumor cells. Proof-of-concept of this innovative method can provide the basis for future studies investigating adoptive cell therapy partnered with nanoparticle-mediated delivery of other immune-boosting agents and drugs for AML, and for other cancers.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
350013
Name
Lou Jenny
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Porphysome mediated delivery of interleukin-2 and in vivo tracking of double negative T-cells for adoptive cell therapy to treat acute myeloid leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Adoptive Cell Therapy; Cancer; Cytokines; Double Negative T-Cells; Immune Therapy; Nanoparticles; Porphysomes; Positron Emission Tomography
Abstract
Acute myeloid leukemia (AML) is a cancer of early stage immune cells and affects mainly individuals over 60 years of age. Since a variety of genetic defects can result in AML, tumors can be different in different individuals. This heterogeneity makes AML difficult to treat with current options like chemotherapy and bone marrow transplantation. With a five year survival rate of 25%, new therapies are needed to improve patient survival. One promising therapy is adoptive cell therapy, in which the patient's immune cells are removed, cloned and injected back into the body to kill tumor cells. However, not all immune cells reach the tumor site and immune cells have a short lifetime of action. To address these problems, we propose a novel method of adoptive cell therapy, in which immune cells are attached to special nanoparticles. These nanoparticles demonstrate imaging abilities and can be loaded with immune-boosting agents. In this way, we can track the real time movement of immune cells and enhance their ability to kill tumor cells. Proof-of-concept of this innovative method can provide the basis for future studies investigating adoptive cell therapy partnered with nanoparticle-mediated delivery of other immune-boosting agents and drugs for AML, and for other cancers.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lou, Jenny
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~